The results of a new study revealed that the property (known as the commercial names is Monjoro and Zondonde) helps to lose weight significantly and sustainable after having used it once a week for at least 3 years for adults with weight gain or obesity that are not diabetics.
The preliminary results of the study on the European association for the study of obesity were presented on April 11, 2025. The remaining details of the study will be revealed in the conference that the association will hold in the period of May 11 to 14 of this year in Malaga, Spain.
The study was supervised by Dr. Luka Bozeto of the Italian University of Badova, in cooperation with Eli Lilly, manufactured for Terzepatid. Dr. Bouzito said that the study results have proven that the response to the drug varies from one person to another, because the two categories react the most to the medication are women and adults who suffer from weight or obesity without diabetes.
The results of the participants who joined the drug for 3 years were divided into 3 categories, the first category has lost 10% of its weight only, which is the fastest category in the firmness stadium. The second category lost 20% of its original weight before reaching weight stability.
Luggish
The third category is the most sensitive to property because it has lost the most important weight frequency, which is 30%, in addition to it, it was slower to reach the stage of stability. And formed women and adults with diabetes, the majority of the third series.
Most of the study participants reached the stage of firmness 6 to 12 months after starting to take the property, but they were able to maintain their new weight. The results of this study confirm the effectiveness of long -term weight injection if it is constantly consumed.
The study has not revealed any new risk to the health of the Terzopatide injection, but confirmed that there were certain common side effects as in previous studies such as the feeling of nausea, diarrhea or constipation.